<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2111222919
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VALGAN 50MG/ML POWDER FOR ORAL SOLUTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Valganciclovir
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1270.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QJ05AB14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Valgan for oral solution 50 mg / 1 mL  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                oral solution 50 mg / 1 mL  
Each ml of constituted oral solution contains Valganciclovir free base 50 mg equivalent to 55. 15 mg of Valganciclovir hvdrochloride USP.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valganciclovir for oral solution 50 mg / 1 mL  
Before Reconstitution: White to slightly yellow powder  
After Reconstitution: Colorless to brownish yellow tutti-frutti flavored solution.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valgan oral Solution is indicated for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS).&nbsp;</p><p>Valgan oral Solution is indicated for the prevention of CMV disease in CMV-negative adults and children (aged from birth to 18 years) who have received a solid organ transplant from a CMVpositive donor.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u> <strong>&nbsp;</strong></p><p><strong>Caution &ndash; Strict adherence to dosage recommendations is essential to avoid overdose (see sections 4.4 and 4.9).</strong>&nbsp;&nbsp;</p><p>Valganciclovir is rapidly and extensively metabolised to ganciclovir after oral dosing. Oral valganciclovir 900 mg taken twice daily is therapeutically equivalent to intravenous ganciclovir 5 mg/kg taken twice daily. The ganciclovir systemic exposure following administration of 900 mg valganciclovir oral solution is equivalent to valganciclovir 900 mg tablets &nbsp;</p><p>&nbsp;</p><p>Treatment of cytomegalovirus (CMV) retinitis&nbsp;</p><p>Module-1&nbsp;</p><p><em>Adult patients </em>&nbsp;<em>Induction treatment of CMV retinitis</em>&nbsp;&nbsp;</p><p>For patients with active CMV retinitis, the recommended dose is 900 mg valganciclovir twice a day for 21 days. Prolonged induction treatment may increase the risk of bone marrow toxicity (see section 4.4).&nbsp;</p><p><em>Maintenance treatment of CMV retinitis:</em>&nbsp;&nbsp;</p><p>Following induction treatment, or in patients with inactive CMV retinitis, the recommended dose is 900 mg valganciclovir once daily. Patients whose retinitis worsens may repeat induction treatment; however, consideration should be given to the possibility of viral drug resistance.&nbsp;</p><p>The duration of maintenance treatment should be determined on an individual basis.&nbsp;</p><p><em>Paediatric population</em>&nbsp;&nbsp;</p><p>The safety and efficacy of Valgan oral Solution in the treatment of CMV retinitis have not been established in adequate and well-controlled clinical studies in paediatric patients.&nbsp;</p><p>Prevention of CMV disease in solid organ transplantation&nbsp; &nbsp;</p><p>Adult patients&nbsp;&nbsp;</p><p>For kidney transplant patients, the recommended dose is 900 mg once daily, starting within 10 days post-transplantation and continuing until 100 days post transplantation. Prophylaxis may be continued until 200 days post-transplantation (see sections 4.4, 4.8 and 5.1).&nbsp;</p><p>For patients who have received a solid organ transplant other than kidney, the recommended dose is 900 mg once daily, starting within 10 days post-transplantation and continuing until 100 days post-transplantation.&nbsp;</p><p>Paediatric population&nbsp; &nbsp;</p><p>In paediatric solid organ transplant patients, aged from birth, who are at risk of developing CMV disease, the recommended once daily dose of Valgan oral Solution is based on body surface area (BSA) and creatinine clearance (Clcr) derived from Schwartz formula (ClcrS), and is calculated using the equation below:&nbsp;</p><p>Paediatric Dose (mg) = 7 x BSA x ClcrS (see Mosteller BSA formula and Schwartz Creatinine Clearance formula below).&nbsp;&nbsp;</p><p>If the calculated Schwartz creatinine clearance exceeds 150 mL/min/1.73m<sup>2</sup>, then a maximum value of 150 mL/min/1.73m<sup>2</sup> should be used in the equation:&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_39634" o:spid="_x0000_s2050" style='width:417.7pt;height:92.4pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="53047,11734" o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Picture_x0020_375" o:spid="_x0000_s2051" type="#_x0000_t75"
  style='position:absolute;width:33058;height:5238;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_377" o:spid="_x0000_s2052" type="#_x0000_t75"
  style='position:absolute;top:6413;width:53047;height:5321;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
   o:title=""/>
 </v:shape><v:rect id="Rectangle_x0020_378" o:spid="_x0000_s2053" style='position:absolute;
  left:33077;top:4244;width:506;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_379" o:spid="_x0000_s2054" style='position:absolute;
  left:33458;top:4244;width:506;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCrw1hLxQAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pa8JA
FMTvhX6H5RW81Y0VqomuIlXRY/0D6u2RfSbB7NuQXU3qp3cLgsdhZn7DjKetKcWNaldYVtDrRiCI
U6sLzhTsd8vPIQjnkTWWlknBHzmYTt7fxpho2/CGblufiQBhl6CC3PsqkdKlORl0XVsRB+9sa4M+
yDqTusYmwE0pv6LoWxosOCzkWNFPTullezUKVsNqdlzbe5OVi9Pq8HuI57vYK9X5aGcjEJ5a/wo/
22utoD+I4f9MOAJy8gAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQCrw1hLxQAAANwAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="347" height="55" alt="" vspace="0" hspace="0" border="0" style="width:347px;height:55px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /></p><p><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:417.7pt;height:92.4pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]-->&nbsp;<img src="data:image/png;base64,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" alt="" width="557" height="56" vspace="0" hspace="0" border="0" style="width:557px;height:56px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>where k = 0.45* for patients aged &lt; 2 years, 0.55 for boys aged 2 to &lt; 13 years and girls aged 2 to 16 years, and 0.7 for boys aged 13 to 16 years. Refer to adult dosing for patients older than 16 years of age.&nbsp;</p><p>The k values provided are based on the Jaffe method of measuring serum creatinine and may require correction when enzymatic methods are used.&nbsp;</p><p>*For appropriate sub-populations a lowering of k value may also be necessary (e.g. in paediatric patients with low birth weight).&nbsp;&nbsp;</p><p>For paediatric kidney transplant patients, the recommended once daily mg dose (7 x BSA x ClcrS) should start within 10 days post-transplantation and continue until 200 days posttransplantation.&nbsp;</p><p>For paediatric patients who have received a solid organ transplant other than kidney, the recommended once daily mg dose (7x BSA x ClcrS) should start within 10 days posttransplantation and continue until 100 days post-transplantation.&nbsp;</p><p>All calculated doses should be rounded to the nearest 25 mg increment for the actual deliverable dose. The oral dispenser is graduated in ml. A 50 mg dose is equivalent to 1 ml:&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td style="vertical-align:top"><p>valganciclovir dose&nbsp;&nbsp;</p></td><td><p>Valgan oral Solution for Oral Solution to be administered&nbsp;</p></td></tr><tr><td><p>50 mg&nbsp;</p></td><td><p>1 ml&nbsp;</p></td></tr><tr><td><p>75 mg&nbsp;</p></td><td><p>1.5 ml&nbsp;</p></td></tr><tr><td><p>100 mg&nbsp;</p></td><td><p>2 ml&nbsp;</p></td></tr><tr><td><p>500 mg&nbsp;</p></td><td><p>10 ml&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>If the calculated dose exceeds 900 mg (2 x 9 ml), a maximum dose of 900 mg (2 x 9 ml) should be administered. The oral solution is the preferred formulation since it provides the ability to administer a dose calculated according to the formula above; however, Valgan oral Solution filmcoated tablets may be used if the calculated doses are within 10% of available tablet doses, and the patient is able to swallow tablets. For example, if the calculated dose is between 405 mg and 495 mg, one 450 mg tablet may be taken.&nbsp;&nbsp;</p><p>It is recommended to monitor serum creatinine levels regularly and consider changes in height and body weight and adapt the dose as appropriate during the prophylaxis period.&nbsp;</p><p><u>Special dosage instructions</u>&nbsp;&nbsp;</p><p>Paediatric population&nbsp; &nbsp;</p><p>Dosing of paediatric SOT patients is individualised based on a patient&#39;s renal function, together with body surface area.&nbsp;</p><p><em>Elderly patients:</em>&nbsp;&nbsp;</p><p>Safety and efficacy have not been established in this patient population. No studies have been conducted in adults older than 65 years of age. Since renal clearance decreases with age, Valgan oral Solution should be administered to elderly patients with special consideration of their renal status (see table below).&nbsp;</p><p>Patients with renal impairment&nbsp; &nbsp;</p><p>Serum creatinine levels or estimated creatinine clearance should be monitored carefully.<strong> </strong>Dosage adjustment is required according to creatinine clearance, as shown in the Table below (see sections 4.4 and 5.2).&nbsp;</p><p>An estimated creatinine clearance (ml/min) can be related to serum creatinine by the following formulae:&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_468" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:295.5pt;
 height:34.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png"
  o:title=""/>
</v:shape><![endif]--><img width="394" height="46" alt="" vspace="0" hspace="0" border="0" style="width:394px;height:46px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" />&nbsp;</p><p>For females = 0.85 &times; male value&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td style="vertical-align:top"><p>Clcr (ml/min)&nbsp;</p></td><td style="vertical-align:top"><p>Induction dose of valganciclovir&nbsp;</p></td><td style="vertical-align:top"><p>Maintenance/Prevention&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dose&nbsp; valganciclovir&nbsp;</p></td><td style="vertical-align:top"><p>of</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_45494" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:108.75pt;
   height:93pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png"
    o:title=""/>
  </v:shape><![endif]--><img width="145" height="124" alt="" vspace="0" hspace="0" border="0" style="width:145px;height:124px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /></p></td><td style="vertical-align:top"><p>900 mg twice daily&nbsp;</p></td><td style="vertical-align:top"><p>900 mg once daily&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>450 mg twice daily&nbsp;</p></td><td style="vertical-align:top"><p>450 mg once daily&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>450 mg once daily&nbsp;</p></td><td style="vertical-align:top"><p>225 mg once daily&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>225 mg once daily&nbsp;</p></td><td style="vertical-align:top"><p>125 mg once daily&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;200 mg three times a week after dialysis&nbsp;</p></td><td style="vertical-align:top"><p>100 mg three times a week after dialysis&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Dosage for patients with renal impairment:&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td style="vertical-align:top"><p>valganciclovir dose&nbsp;&nbsp;</p></td><td><p>Valgan oral Solution for Oral Solution to be administered&nbsp;</p></td></tr><tr><td><p>125 mg&nbsp;</p></td><td><p>2.5 ml&nbsp;</p></td></tr><tr><td><p>225 mg&nbsp;</p></td><td><p>4.5 ml&nbsp;</p></td></tr><tr><td><p>450 mg&nbsp;</p></td><td><p>9 ml&nbsp;</p></td></tr></tbody></table><p><em>&nbsp;</em>&nbsp;</p><p><em>Patients undergoing haemodialysis:</em>&nbsp;&nbsp;</p><p>Dosage adjustment is necessary for patients on haemodialysis (Clcr &lt;10ml/min) (see sections 4.4 and 5.2) and a dosing recommendation is given in the Table above.&nbsp;</p><p>Patients with hepatic impairment&nbsp; &nbsp;</p><p>Safety and efficacy of Valgan oral Solution have not been established in patients with hepatic impairment (see section 5.2).&nbsp;</p><p><em>Patients with severe leukopenia, neutropenia, anaemia, thrombocytopenia and pancytopenia:</em>&nbsp;&nbsp;</p><p>See section 4.4 before initiation of therapy. If there is a significant deterioration of blood cell counts during therapy with Valgan oral Solution, treatment with haematopoietic growth factors and/or dose interruption should be considered (see section 4.4).&nbsp;</p><p><u>Method of administration</u>&nbsp;&nbsp;</p><p>Valgan oral Solution is administered orally, and whenever possible, should be taken with food (see section 5.2).&nbsp;</p><p>Precautions to be taken before handling or administering the medicinal product &nbsp;&nbsp;</p><p>Valgan oral Solution powder for oral solution requires reconstitution prior to oral administration. Two oral dosing dispensers that are graduated to 10 ml (500 mg), with 0.5 ml (25 mg) graduations are provided. It is recommended that patients use the dispenser. For instructions on reconstitution of the medicinal product before administration, see sections 4.4 and 6.6.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valgan oral Solution is contraindicated in patients with hypersensitivity to valganciclovir, ganciclovir or to any of the excipients listed in section 6.1.   
Valgan oral Solution is contraindicated during breast-feeding (see section 4.6).  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cross-hypersensitivity</u>&nbsp;&nbsp;</p><p>Due to the similarity of the chemical structure of ganciclovir and that of aciclovir and penciclovir, a cross-hypersensitivity reaction between these drugs is possible. Caution should therefore be used when prescribing Valgan oral Solution to patients with known hypersensitivity to aciclovir or penciclovir, (or to their prodrugs, valaciclovir or famciclovir respectively).&nbsp;</p><p><u>Precautions to be taken before handling</u>&nbsp;&nbsp;</p><p>Owing to the teratogenic character, the Valgan oral Solution powder and reconstituted solution should be handled with caution. Inhalation should be avoided. If the powder or solution make direct contact with skin, the area should be washed thoroughly with soap and water. If the solution gets into the eye, the eye should be thoroughly washed with water immediately (see section 6.6).&nbsp;</p><p><u>Mutagenicity, teratogenicity, carcinogenicity, fertility and contraception</u>&nbsp;&nbsp;</p><p>Prior to the initiation of valganciclovir treatment, patients should be advised of the potential risks to the foetus. In animal studies, ganciclovir was found to be mutagenic, teratogenic, carcinogenic, and a suppressor of fertility. Valgan oral Solution should, therefore, be considered a potential teratogen and carcinogen in humans with the potential to cause birth defects and cancers (see section 5.3). Based on clinical and nonclinical studies it is also considered likely that Valgan oral Solution causes temporary or permanent inhibition of spermatogenesis. Women of child bearing potential must be advised to use effective contraception during and for at least 30 days after treatment. Men must be advised to practise barrier contraception during treatment, and for at least 90 days thereafter, unless it is certain that the female partner is not at risk of pregnancy (see sections</p><p>4.6, 4.8 and 5.3).&nbsp;</p><p>Valganciclovir has the potential to cause carcinogenicity and reproductive toxicity in the long term.&nbsp;</p><p><u>Myelosuppression</u>&nbsp;&nbsp;</p><p>Severe leukopenia, neutropenia, anaemia, thrombocytopenia, pancytopenia, bone marrow failure and aplastic anaemia have been observed in patients treated with Valgan oral Solution (and ganciclovir). Therapy should not be initiated if the absolute neutrophil count is less than 500 cells/&mu;l, or the platelet count is less than 25000/&mu;l, or the haemoglobin level is less than 8g/dl (see sections 4.2 and 4.8).&nbsp;</p><p>When extending prophylaxis beyond 100 days the possible risk of developing leukopenia and neutropenia should be taken into account (see sections 4.2, 4.8 and 5.1).&nbsp;</p><p>Valgan oral Solution should be used with caution in patients with pre-existing haematological cytopenia or a history of drug-related haematological cytopenia and in patients receiving radiotherapy.&nbsp;</p><p>It is recommended that complete blood counts and platelet counts should be monitored regularly during therapy. Increased haematological monitoring may be warranted in patients with renal impairment and paediatrics, at a minimum each time the patient attends the transplant clinic.<strong> </strong>In patients developing severe leukopenia, neutropenia, anaemia and/or thrombocytopenia, it is recommended that treatment with haematopoietic growth factors and/or dose interruption be considered (see sections 4.2 and 4.8).&nbsp;</p><p><u>Renal impairment</u>&nbsp;&nbsp;</p><p>In patients with impaired renal function, dosage adjustments based on creatinine clearance are required (see sections 4.2 and 5.2).&nbsp;</p><p><u>Use with other medicines</u>&nbsp;&nbsp;</p><p>Seizures have been reported in patients taking imipenem-cilastatin and ganciclovir. Valgan oral Solution should not be used concomitantly with imipenem-cilastatin unless the potential benefits outweigh the potential risks (see section 4.5).&nbsp;</p><p>Patients treated with Valgan oral Solution and (a) didanosine, (b) drugs that are known to be myelosuppressive (e.g. zidovudine), or (c) substances affecting renal function, should be closely monitored for signs of added toxicity (see section 4.5).&nbsp;</p><p>The controlled clinical study using valganciclovir for the prophylactic treatment of CMV disease in transplantation, as detailed in section 5.1, did not include lung and intestinal transplant patients.</p><p>Therefore, experience in these transplant patients is limited.&nbsp;</p><p><u>Controlled diet</u>&nbsp;&nbsp;</p><p>For patients on a sodium-controlled diet, this medicinal product contains a total of 0.188 mg/ml sodium (essentially &#39;sodium-free&#39;).&nbsp;</p><p>Benzoic acid and benzoates (sodium benzoate)&nbsp;</p><p>This medicine contains 100mg of sodium benzoate in each 12g bottle, which is equivalent to 1mg/ml after reconstitution. Benzoate salt may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Drug interactions with valganciclovir</u>&nbsp;&nbsp;</p><p><em>In-vivo</em> drug interaction studies with Valgan oral Solution have not been performed. Since valganciclovir is extensively and rapidly metabolised to ganciclovir; drug interactions associated with ganciclovir will be expected for valganciclovir.&nbsp;</p><p><u>Drug interactions with ganciclovir</u>&nbsp;&nbsp;</p><p><em><u>Pharmacokinetic interactions</u> </em>&nbsp;&nbsp;</p><p>Probenecid&nbsp; &nbsp;</p><p>Probenecid given with oral ganciclovir resulted in statistically significantly decreased renal clearance of ganciclovir (20%) leading to statistically significantly increased exposure (40%). These changes were consistent with a mechanism of interaction involving competition for renal tubular secretion. Therefore, patients taking probenecid and valganciclovir should be closely monitored for ganciclovir toxicity.&nbsp;</p><p>Didanosine&nbsp; &nbsp;</p><p>Didanosine plasma concentrations were found to be consistently raised when given with IV ganciclovir. At intravenous doses of 5 and 10 mg/kg/day, an increase in the AUC of didanosine ranging from 38 to 67% has been observed, confirming a pharmacokinetic interaction during the concomitant administration of these drugs. There was no significant effect on ganciclovir concentrations. Patients should be closely monitored for didanosine toxicity e.g pancreatitis (see section 4.4)&nbsp;</p><p>Other antiretrovirals &nbsp;&nbsp;</p><p>Cytochrome P450 isoenzymes play no role in ganciclovir pharmacokinetics. As a consequence, pharmacokinetic interactions with protease inhibitors and non-nucleoside reverse transcriptase inhibitors are not anticipated.&nbsp;</p><p><em><u>Pharmacodynamic interactions</u> </em>&nbsp;&nbsp;</p><p>Imipenem-cilastatin&nbsp; &nbsp;</p><p>Seizures have been reported in patients taking ganciclovir and imipenem-cilastatin concomitantly and a pharmacodynamic interaction between these two drugs cannot be discounted. These drugs should not be used concomitantly unless the potential benefits outweigh the potential risks (see section 4.4). <em>Zidovudine</em>&nbsp;&nbsp;</p><p>Both zidovudine and ganciclovir have the potential to cause neutropenia and anaemia. A pharmacodynamic interaction may occur during concomitant administration of these drugs. Some patients may not tolerate concomitant therapy at full dosage (see section 4.4).&nbsp;</p><p>Potential drug interactions&nbsp; &nbsp;</p><p>Toxicity may be enhanced when ganciclovir/valganciclovir is co-administered with other drugs known to be myelosuppressive or associated with renal impairment. This includes nucleoside (e.g. zidovudine, didanosine, stavudine) and nucleotide analogues (e.g. tenofovir, adefovir), immunosuppressants (e.g. ciclosporin, tacrolimus, mycophenolate mofetil), antineoplastic agents (e.g. doxorubicin, vinblastine, vincristine, hydroxyurea) and anti-infective agents (trimethoprim/sulphonamides, dapsone, amphotericin B, flucytosine, pentamidine). Therefore, these drugs should only be considered for concomitant use with valganciclovir if the potential benefits outweigh the potential risks (see section 4.4).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Contraception in males and females</u>&nbsp;&nbsp;</p><p>As a result of the potential for reproductive toxicity and teratogenicity, women of childbearing potential must be advised to use effective contraception during and for at least 30 days after treatment. Male patients must be advised to practice barrier contraception during and for at least 90 days following treatment with valganciclovir unless it is certain that the female partner is not at risk of pregnancy (see sections 4.4 and 5.3).&nbsp;</p><p><u>Pregnancy</u>&nbsp;&nbsp;</p><p>The safety of Valgan oral Solution for use in pregnant women has not been established. Its active metabolite, ganciclovir, readily diffuses across the human placenta. Based on its pharmacological mechanism of action and reproductive toxicity observed in animal studies with ganciclovir (see section 5.3) there is a theoretical risk of teratogenicity in humans.&nbsp;</p><p>Valgan oral Solution should not be used in pregnancy unless the therapeutic benefit for the mother outweighs the potential risk of teratogenic damage to the foetus.&nbsp;</p><p><u>Breast-feeding</u>&nbsp;&nbsp;</p><p>It is unknown if ganciclovir is excreted in human breast milk, but the possibility of ganciclovir being excreted in the breast milk and causing serious adverse reactions in the nursing infant cannot be discounted. Animal data indicate that ganciclovir is excreted in the milk of lactating rats Therefore, breast-feeding must be discontinued during treatment with valganciclovir (see sections</p><p>4.3 and 5.3).&nbsp;</p><p><u>Fertility</u>&nbsp;&nbsp;</p><p>A small clinical study with renal transplant patients receiving Valgan oral Solution for CMV prophylaxis for up to 200 days demonstrated an impact of valganciclovir on spermatogenesis, with decreased sperm density and motility measured after treatment completion. This effect appears to be reversible and approximately six months after Valgan oral Solution discontinuation, mean sperm density and motility recovered to levels comparable to those observed in the untreated controls.&nbsp;</p><p>In animal studies, ganciclovir impaired fertility in male and female mice and has shown to inhibit spermatogenesis and induce testicular atrophy in mice, rats and dogs at doses considered clinically relevant.&nbsp;</p><p>Based on clinical and nonclinical studies, it is considered likely that ganciclovir (and valganciclovir) may cause temporary or permanent inhibition of human spermatogenesis (see sections 4.4 and 5.3).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.&nbsp;</p><p>Adverse reactions such as seizures, dizziness and confusion have been reported with the use of Valgan oral Solution and/or ganciclovir. If they occur, such effects may affect the patient&#39;s ability to drive and operate machinery.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>a </em></strong></p><p><strong>Summary of the safety profile</strong><strong> </strong>&nbsp;&nbsp;</p><p>Valganciclovir is a prodrug of ganciclovir, which is rapidly and extensively metabolised to ganciclovir after oral administration. The undesirable effects known to be associated with ganciclovir use can be expected to occur with valganciclovir. All of the adverse drug reactions observed in valganciclovir clinical studies have been previously observed with ganciclovir. Therefore, adverse drug reactions reported with IV or oral ganciclovir (formulation no longer available) or with valganciclovir are included in the table of adverse drug reactions below.&nbsp;</p><p>In patients treated with valganciclovir/ganciclovir the most serious and frequent adverse drug reactions are haematological reactions and include neutropenia, anaemia and thrombocytopenia &ndash; see section 4.4.&nbsp;</p><p>The frequencies presented in the table of adverse reactions are derived from a pooled population of patients (n=1704) receiving maintenance therapy with ganciclovir or valganciclovir. Exception is made for anaphylactic reaction, agranulocytosis and granulocytopenia, the frequencies of which are derived from post-marketing experience. Adverse reactions are listed according to MedDRA system organ class. Frequency categories are defined using the following convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000) and very rare (&lt; 1/10,000).&nbsp;</p><p>The overall safety profile of ganciclovir/valganciclovir is consistent in HIV and transplant populations except that retinal detachment has only been reported in patients with CMV retinitis. However, there are some differences in the frequency of certain reactions. Valganciclovir is associated with a higher risk of diarrhoea compared to intravenous ganciclovir. Pyrexia, candida infections, depression, severe neutropenia (ANC &lt;500/&mu;L) and skin reactions are reported more frequently in patients with HIV. Renal and hepatic dysfunction are reported more frequently in organ transplant recipients.&nbsp;</p><p><strong>b Tabulated list of adverse drug reactions</strong><strong> </strong>&nbsp;&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td><p><strong>ADR</strong>&nbsp;&nbsp;</p><p><strong>(MedDRA) </strong>&nbsp;&nbsp;</p><p><strong>System Organ Class</strong>&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p><strong>Frequency Category</strong>&nbsp;</p></td></tr><tr><td><p><strong><em>Infections and infestations:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Candida infections including oral candidiasis.&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>Very common&nbsp;</p></td></tr><tr><td><p>Upper respiratory tract infection&nbsp;</p></td></tr><tr><td><p>Sepsis&nbsp;&nbsp;</p></td><td rowspan="4" style="vertical-align:top"><p>Common&nbsp;</p></td></tr><tr><td><p>Influenza&nbsp;</p></td></tr><tr><td><p>Urinary tract infection&nbsp;</p></td></tr><tr><td><p>Cellulitis&nbsp;</p></td></tr><tr><td><p><strong><em>Blood and lymphatic disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Neutropenia&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>Very common&nbsp;</p></td></tr><tr><td><p>Anaemia&nbsp;</p></td></tr><tr><td><p>Thrombocytopenia&nbsp;</p></td><td><p>Common&nbsp;</p></td></tr><tr><td><p>Leukopenia&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Pancytopenia&nbsp;</p></td></tr><tr><td><p>Bone marrow failure&nbsp;</p></td><td><p>Uncommon&nbsp;</p></td></tr><tr><td><p>Aplastic anaemia&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>Rare&nbsp;</p></td></tr><tr><td><p>Agranulocytosis*&nbsp;</p></td></tr><tr><td><p>Granulocytopenia*&nbsp;</p></td></tr><tr><td><p><strong><em>Immune system disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hypersensitivity&nbsp;</p></td><td><p>Common&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td><p>Anaphylactic reaction*&nbsp;</p></td><td><p>Rare&nbsp;</p></td></tr><tr><td><p><strong><em>Metabolic and nutrition disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Decreased appetite&nbsp;&nbsp;</p></td><td><p>Very common&nbsp;</p></td></tr><tr><td><p>Weight decreased&nbsp;</p></td><td><p>Common&nbsp;</p></td></tr><tr><td><p><strong><em>Psychiatric disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Depression&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>Common&nbsp;</p></td></tr><tr><td><p>Confusional state&nbsp;</p></td></tr><tr><td><p>Anxiety&nbsp;</p></td></tr><tr><td><p>Agitation&nbsp;</p></td><td rowspan="4" style="vertical-align:top"><p>Uncommon&nbsp;</p></td></tr><tr><td><p>Psychotic disorder&nbsp;</p></td></tr><tr><td><p>Thinking abnormal&nbsp;</p></td></tr><tr><td><p>Hallucinations&nbsp;</p></td></tr><tr><td><p><strong><em>Nervous system disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Headache&nbsp;</p></td><td><p>Very common&nbsp;</p></td></tr><tr><td><p>Insomnia&nbsp;</p></td><td rowspan="4" style="vertical-align:top"><p>Common&nbsp;</p></td></tr><tr><td><p>Neuropathy peripheral&nbsp;</p></td></tr><tr><td><p>Dizziness&nbsp;</p></td></tr><tr><td><p>Paraesthesia&nbsp;</p></td></tr><tr><td><p>Hypoaesthesia&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Seizure&nbsp;</p></td></tr><tr><td><p>Dysgeusia (taste disturbance)&nbsp;</p></td></tr><tr><td><p>Tremor&nbsp;</p></td><td><p>Uncommon&nbsp;</p></td></tr><tr><td><p><strong><em>Eye disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Visual impairment&nbsp;</p></td><td rowspan="6" style="vertical-align:top"><p>Common&nbsp;</p></td></tr><tr><td><p>Retinal detachment**&nbsp;</p></td></tr><tr><td><p>Vitreous floaters&nbsp;</p></td></tr><tr><td><p>Eye pain&nbsp;</p></td></tr><tr><td><p>Conjunctivitis&nbsp;</p></td></tr><tr><td><p>Macular oedema&nbsp;</p></td></tr><tr><td><p><strong><em>Ear and labyrinth disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Ear pain&nbsp;</p></td><td><p>Common&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td><p>Deafness&nbsp;</p></td><td><p>Uncommon&nbsp;</p></td></tr><tr><td><p><strong><em>Cardiac disorders</em></strong><em>:</em>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmias&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon&nbsp;</p><p>&nbsp;</p></td></tr><tr><td><p><strong><em>Vascular disorders</em></strong><em>:</em>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hypotension&nbsp;</p></td><td><p>Common&nbsp;</p></td></tr><tr><td><p><strong><em>Respiratory, thoracic and mediastinal disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Cough&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>Very common&nbsp;</p></td></tr><tr><td><p>Dyspnoea&nbsp;</p></td></tr><tr><td><p><strong><em>Gastrointestinal disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Diarrhoea&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>Very common&nbsp;</p></td></tr><tr><td><p>Nausea&nbsp;</p></td></tr><tr><td><p>Vomiting&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td><p>Abdominal pain&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Dyspepsia&nbsp;</p></td><td rowspan="8" style="vertical-align:top"><p>Common&nbsp;</p></td></tr><tr><td><p>Flatulence&nbsp;</p></td></tr><tr><td><p>Abdominal pain upper&nbsp;</p></td></tr><tr><td><p>Constipation&nbsp;</p></td></tr><tr><td><p>Mouth ulceration&nbsp;</p></td></tr><tr><td><p>Dysphagia&nbsp;</p></td></tr><tr><td><p>Abdominal distention&nbsp;</p></td></tr><tr><td><p>Pancreatitis&nbsp;</p></td></tr><tr><td><p><strong><em>Hepato-biliary disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Blood alkaline phosphatase increased&nbsp;</p></td><td rowspan="4" style="vertical-align:top"><p>Common&nbsp;</p></td></tr><tr><td><p>Hepatic function abnormal&nbsp;</p></td></tr><tr><td><p>Aspartate aminotransferase increased&nbsp;</p></td></tr><tr><td><p>Alanine aminotransferase increased&nbsp;</p></td></tr><tr><td><p><strong><em>Skin and subcutaneous tissues disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Dermatitis&nbsp;</p></td><td><p>Very common&nbsp;</p></td></tr><tr><td><p>Night sweats&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>Common&nbsp;</p></td></tr><tr><td><p>Pruritus&nbsp;</p></td></tr><tr><td><p>Rash&nbsp;</p></td></tr><tr><td><p>Alopecia&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Dry skin&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>Uncommon&nbsp;</p></td></tr><tr><td><p>Urticaria&nbsp;</p></td></tr><tr><td><p><strong><em>Musculo-skeletal and connective tissue disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Back pain&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>Common&nbsp;</p></td></tr><tr><td><p>Myalgia&nbsp;</p></td></tr><tr><td><p>Arthralgia&nbsp;</p></td></tr><tr><td><p>Muscle spasms&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p><strong><em>Renal and urinary disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Renal impairment&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>Common&nbsp;</p></td></tr><tr><td><p>Creatinine clearance renal decreased&nbsp;&nbsp;</p></td></tr><tr><td><p>Blood creatinine increased&nbsp;&nbsp;</p></td></tr><tr><td><p>Renal failure&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>Uncommon&nbsp;</p></td></tr><tr><td><p>Haematuria&nbsp;</p></td></tr><tr><td><p><strong><em>Reproductive system and breast disorders:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Infertility male&nbsp;</p></td><td><p>Uncommon&nbsp;</p></td></tr><tr><td><p><strong><em>General disorders and administration site conditions:</em> </strong>&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Pyrexia&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>Very common&nbsp;</p></td></tr><tr><td><p>Fatigue&nbsp;</p></td></tr><tr><td><p>Pain&nbsp;</p></td><td rowspan="4" style="vertical-align:top"><p>Common&nbsp;</p></td></tr><tr><td><p>Chills&nbsp;</p></td></tr><tr><td><p>Malaise&nbsp;</p></td></tr><tr><td><p>Asthenia&nbsp;</p></td></tr><tr><td><p>Chest pain&nbsp;</p></td><td><p>Uncommon&nbsp;</p></td></tr></tbody></table><p><em>&nbsp;</em>&nbsp;</p><p><em>*The frequencies of these adverse reactions are derived from post-marketing experience</em>&nbsp; <em>**Retinal detachment has only been reported in HIV patients treated for CMV retinitis</em>&nbsp; <em>Description of selected adverse reactions</em>&nbsp; <em>Neutropenia</em>&nbsp; <em>&nbsp;</em></p><p>The risk of neutropenia is not predictable on the basis of the number of neutrophils before treatment. Neutropenia usually occurs during the first or second week of induction therapy. The cell count usually normalises within 2 to 5 days after discontinuation of the drug or dose reduction (see section 4.4).&nbsp;</p><p><em>Thrombocytopenia</em>&nbsp; <em>&nbsp;</em></p><p>Patients with low baseline platelet counts (&lt; 100,000 /&mu;L) have an increased risk of developing thrombocytopenia. Patients with iatrogenic immunosuppression due to treatment with immunosuppressive drugs are at greater risk of thrombocytopenia than patients with AIDS (see section 4.4). Severe thrombocytopenia may be associated with potentially life-threatening bleeding.&nbsp;</p><p><em>Influence of treatment duration or indication on adverse reactions</em>&nbsp; <em>&nbsp;</em></p><p>Severe neutropenia (ANC &lt;500/&mu;L) is seen more frequently in CMV retinitis patients (14%) undergoing treatment with valganciclovir, intravenous or oral ganciclovir than in solid organ transplant patients receiving valganciclovir or oral ganciclovir. In patients receiving valganciclovir or oral ganciclovir until Day 100 post-transplant, the incidence of severe neutropenia was 5% and 3% respectively, whilst in patients receiving valganciclovir until Day 200 post-transplant the incidence of severe neutropenia was 10%.&nbsp;&nbsp;</p><p>There was a greater increase in serum creatinine seen in solid organ transplant patients treated until Day 100 or Day 200 post-transplant with both valganciclovir and oral ganciclovir when compared to CMV retinitis patients. However, impaired renal function is a feature common in solid organ transplantation patients.&nbsp;</p><p>The overall safety profile of Valgan oral Solution did not change with the extension of prophylaxis up to 200 days in high risk kidney transplant patients. Leukopenia was reported with a slightly higher incidence in the 200 days arm while the incidence of neutropenia, anaemia and thrombocytopenia were similar in both arms.&nbsp;</p><p>c Paediatric population &nbsp;&nbsp;</p><p>Valgan oral Solution has been studied in 179 paediatric solid organ transplant patients who were at risk of developing CMV disease (aged 3 weeks to 16 years) and in 133 neonates with symptomatic congenital CMV disease (aged 2 to 31 days), with duration of ganciclovir exposure ranging from 2 to 200 days.&nbsp;&nbsp;</p><p>The most frequently reported adverse reactions on treatment in paediatric clinical trials were diarrhoea, nausea, neutropenia, leukopenia and anaemia.&nbsp;&nbsp;</p><p>In solid organ transplant patients, the overall safety profile was similar in paediatric patients as compared to adults. Neutropenia was reported with slightly higher incidence in the two studies conducted in paediatric solid organ transplant patients as compared to adults, but there was no correlation between neutropenia and infectious adverse events in the paediatric population. A higher risk of cytopenias in neonates and infants warrants careful monitoring of blood counts in these age groups (see section 4.4).&nbsp;</p><p>In kidney transplant paediatric patients, prolongation of valganciclovir exposure up to 200 days was not associated with an overall increase in the incidence of adverse events. The incidence of severe neutropenia (ANC &lt; 500/&micro;L) was higher in paediatric kidney patients treated until Day 200 as compared to paediatric patients treated until Day 100 and as compared to adult kidney transplant patients treated until Day 100 or Day 200 (see section 4.4).&nbsp;</p><p>Only limited data are available in neonates or infants with symptomatic congenital CMV infection treated with Valgan oral Solution, however the safety appears to be consistent with the known safety profile of valganciclovir/ganciclovir.&nbsp;</p><p><u>Reporting of suspected adverse reactions</u>&nbsp;&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.&nbsp;</p><p><strong><em>&bull; </em>Saudi Arabia<em>: </em></strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:510px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662 o Call NPC at +966-11-2038222, Exts: 2317-23562353-235423342340.&nbsp;<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />oWebsite: www.sfda.gov.sa/npc&nbsp;</p></td></tr></tbody></table><p>&nbsp;<strong>o Other GCC States: </strong>&nbsp;</p><p>&nbsp;Please contact the relevant competent authority.<strong> </strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Overdose experience with valganciclovir and intravenous ganciclovir</u>&nbsp;&nbsp;</p><p>It is expected that an overdose of valganciclovir could possibly result in increased renal toxicity (see section 4.2 and section 4.4).&nbsp;</p><p>Reports of overdoses with intravenous ganciclovir, some with fatal outcomes, have been received from clinical trials and during post-marketing experience. In some of these cases no adverse events were reported. The majority of patients experienced one or more of the following adverse events:&nbsp;</p><p><em>Haematological toxicity: </em>myelosuppression including pancytopenia,bone marrow failure, leukopenia, neutropenia, granulocytopenia.&nbsp;</p><p>&ndash;&nbsp; <em>Hepatotoxicity</em>: hepatitis, liver function disorder&nbsp;</p><p>&ndash;&nbsp; <em>Renal toxicity</em>: worsening of haematuria in a patient with pre-existing renal impairment, acute kidney injury, elevated creatinine&nbsp;</p><p>&ndash;&nbsp; <em>Gastrointestinal toxicity</em>: abdominal pain, diarrhoea, vomiting&nbsp;</p><p>&ndash;&nbsp; <em>Neurotoxicity: </em>generalised tremor, seizure&nbsp;</p><p>Haemodialysis and hydration may be of benefit in reducing blood plasma levels in patients who receive an overdose of valganciclovir (see section 5.2).&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antivirals for systemic use, nucleosides and nucleotides excl. reverse transcriptase inhibitors,&nbsp;&nbsp;</p><p>ATC code: J05A B14&nbsp;&nbsp;</p><p><u>Mechanism of action</u>&nbsp;&nbsp;</p><p>Valganciclovir is an L-valyl ester (prodrug) of ganciclovir. After oral administration, valganciclovir is rapidly and extensively metabolised to ganciclovir by intestinal and hepatic esterases. Ganciclovir is a synthetic analogue of 2&#39;-deoxyguanosine and inhibits replication of herpes viruses <em>in vitro</em> and <em>in vivo</em>. Sensitive human viruses include human cytomegalovirus (HCMV), herpes simplex virus-1 and -2 (HSV-1 and HSV-2), human herpes virus -6, -7 and -8 (HHV-6, HHV-7, HHV-8), Epstein-Barr virus (EBV), varicella-zoster virus (VZV) and hepatitis B virus (HBV).&nbsp;&nbsp;</p><p>In CMV-infected cells, ganciclovir is initially phosphorylated to ganciclovir monophosphate by the viral protein kinase, pUL97. Further phosphorylation occurs by cellular kinases to produce ganciclovir triphosphate, which is then slowly metabolised intracellularly. Triphosphate metabolism has been shown to occur in HSV- and HCMV- infected cells with half-lives of 18 and between 6 and 24 hours respectively, after the removal of extracellular ganciclovir. As the phosphorylation is largely dependent on the viral kinase, phosphorylation of ganciclovir occurs preferentially in virus-infected cells.&nbsp;</p><p>The virustatic activity of ganciclovir is due to inhibition of viral DNA synthesis by: (a) competitive inhibition of incorporation of deoxyguanosine-triphosphate into DNA by viral DNA polymerase, and (b) incorporation of ganciclovir triphosphate into viral DNA causing termination of, or very limited, further viral DNA elongation.&nbsp;</p><p><u>Antiviral Activity</u>&nbsp;&nbsp;</p><p>The <em>in-vitro</em> anti-viral activity, measured as IC<sub>50</sub> of ganciclovir against CMV, is in the range of 0.08&mu;M (0.02&mu;g/ml) to 14&mu;M (3.5&mu;g/ml). &nbsp;</p><p>The clinical antiviral effect of Valgan oral Solution has been demonstrated in the treatment of</p><p>AIDS patients with newly diagnosed CMV retinitis. CMV shedding was decreased in urine from 46% (32/69) of patients at study entry to 7% (4/55) of patients following four weeks of Valgan oral Solution treatment.&nbsp;</p><p><u>Clinical efficacy and safety</u>&nbsp; <u>Adult patients</u>&nbsp;&nbsp;</p><p><em>Treatment of CMV retinitis:</em>&nbsp;&nbsp;</p><p>Patients with newly diagnosed CMV retinitis were randomised in one study to induction therapy with either Valgan oral Solution 900 mg (twice daily) or intravenous ganciclovir 5 mg/kg (twice daily). The proportion of patients with photographic progression of CMV retinitis at week 4 was comparable in both treatment groups, 7/70 and 7/71 patients progressing in the intravenous ganciclovir and valganciclovir arms respectively.&nbsp;</p><p>Following induction treatment dosing, all patients in this study received maintenance treatment with Valgan oral Solution given at the dose of 900 mg once daily. The mean (median) time from randomisation to progression of CMV retinitis in the group receiving induction and maintenance treatment with Valgan oral Solution was 226 (160) days and in the group receiving induction treatment with intravenous ganciclovir and maintenance treatment with Valgan oral Solution was 219 (125) days.&nbsp;</p><p><em>Prevention of CMV disease in transplantation</em>&nbsp; <em>&nbsp;</em></p><p>A double-blind, double-dummy clinical active comparator study has been conducted in heart, liver and kidney transplant patients (lung and gastro-intestinal transplant patients were not included in the study) at high-risk of CMV disease (D+/R-) who received either Valgan oral Solution (900 mg once daily) or oral ganciclovir (1000 mg three times daily) starting within 10 days of transplantation until Day 100 post-transplant. The incidence of CMV disease (CMV syndrome + tissue invasive disease) during the first 6 months post-transplant was 12.1% in the Valgan oral Solution arm (n=239) compared with 15.2% in the oral ganciclovir arm (n=125). The large majority of cases occurred following cessation of prophylaxis (post-Day 100) with cases in the valganciclovir arm occurring on average later than those in the oral ganciclovir arm. The incidence of acute rejection in the first 6 months was 29.7% in patients randomised to valganciclovir compared with 36.0% in the oral ganciclovir arm, with the incidence of graft loss being equivalent, occurring in 0.8% of patients, in each arm.&nbsp;</p><p>A double-blind, placebo controlled study has been conducted in 326 kidney transplant patients at high risk of CMV disease (D+/R-) to assess the efficacy and safety of extending Valgan oral Solution CMV prophylaxis from 100 to 200 days post-transplant. Patients were randomized (1:1) to receive Valgan oral Solution tablets (900 mg od) within 10 days of transplantation either until Day 200 post-transplant or until Day 100 post-transplant followed by 100 days of placebo. The proportion of patients who developed CMV disease during the first 12 months post-transplant is shown in the table below.&nbsp;</p><p>Percentage of Kidney Transplant Patients with CMV Disease<sup>1</sup>, 12 Month ITT Population <sup>A</sup>&nbsp; &nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>Valganciclovir </strong>&nbsp;&nbsp;</p><p><strong>900 mg od</strong>&nbsp;&nbsp;</p><p><strong>100 Days</strong>&nbsp;&nbsp;</p><p><strong>N = 163</strong>&nbsp;&nbsp;</p></td><td><p><strong>Valganciclovir </strong>&nbsp;&nbsp;</p><p><strong>900 mg od</strong>&nbsp;&nbsp;</p><p><strong>200 Days</strong>&nbsp;&nbsp;</p><p><strong>N = 155</strong>&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p><strong>Between Treatment </strong></p><p><strong>Group Difference</strong>&nbsp;&nbsp;</p></td></tr><tr><td><p>Patients &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confirmed assumed CMV disease<sup>2</sup>&nbsp;</p></td><td style="vertical-align:top"><p>or</p></td><td><p>71 (43.6%)&nbsp;</p><p>[35.8% ; 51.5%]&nbsp;</p></td><td><p>36 (23.2%)&nbsp;</p><p>[16.8% ; 30.7%]&nbsp;</p></td><td><p>20.3%&nbsp;</p><p>[9.9% ; 30.8%]&nbsp;</p></td></tr><tr><td><p>Patients with confirmed CMV disease&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>60 (36.8%)&nbsp;</p><p>[29.4% ; 44.7%]&nbsp;</p></td><td><p>25 (16.1%)&nbsp;</p><p>[10.7% ; 22.9%]&nbsp;</p></td><td><p>20.7%&nbsp;</p><p>[10.9% ; 30.4%]&nbsp;</p></td></tr></tbody></table><p>&nbsp;&nbsp;</p><p><sup>1 </sup>CMV Disease is defined as either CMV syndrome or tissue invasive CMV. <sup>2</sup> Confirmed CMV is a clinically confirmed case of CMV disease. Patients were assumed to have CMV disease if there was no week 52 assessment and no confirmation of CMV disease before this time point.&nbsp;</p><p><sup>A</sup> The results found up to 24 months were in line with the up to 12 month results: Confirmed or assumed CMV disease was 48.5% in the 100 days treatment arm versus 34.2% in the 200 days treatment arm; difference between the treatment groups was 14.3% [3.2 %; 25.3%].&nbsp;</p><p>Significantly less high risk kidney transplant patients developed CMV disease following CMV prophylaxis with Valgan oral Solution until Day 200 post-transplant compared to patients who received CMV prophylaxis with Valgan oral Solution until Day 100 post-transplant.&nbsp;</p><p>The graft survival rate as well as the incidence of biopsy proven acute rejection was similar in both treatment groups. The graft survival rate at 12 months post-transplant was 98.2% (160/163) for the 100 day dosing regimen and 98.1% (152/155) for the 200 day dosing regimen. Up to 24 month post-transplant, four additional cases of graft loss were reported, all in the 100 days dosing group. The incidence of biopsy proven acute rejection at 12 months post-transplant was &nbsp;</p><p>17.2% (28/163) for the 100 day dosing regimen and 11.0% (17/155) for the 200 day dosing regimen. Up to 24 month post-transplant, one additional case has been reported in the 200 days dosing group.&nbsp;</p><p><u>Viral Resistance</u>&nbsp;&nbsp;</p><p>Virus resistant to ganciclovir can arise after chronic dosing with valganciclovir by selection of mutations in the viral kinase gene (UL97) responsible for ganciclovir monophosphorylation and/or the viral polymerase gene (UL54). In clinical isolates, seven canonical UL97 substitutions, M460V/I, H520Q, C592G, A594V, L595S, C603W are the most frequently reported ganciclovir resistance-associated substitutions. Viruses containing mutations in the UL97 gene are resistant to ganciclovir alone, whereas viruses with mutations in the UL54 gene are resistant to ganciclovir but may show cross-resistance to other antivirals that also target the viral polymerase.&nbsp;</p><p><em>Treatment of CMV retinitis:</em>&nbsp;&nbsp;</p><p>Genotypic analysis of CMV in polymorphonuclear leucocytes (PMNL) isolates from 148 patients with CMV retinitis enrolled in one clinical study has shown that 2.2%, 6.5%, 12.8%, and 15.3% contain UL97 mutations after 3, 6, 12 and 18 months, respectively, of valganciclovir treatment.&nbsp;</p><p><em>Prevention of CMV disease in transplantation:</em>&nbsp; &nbsp;</p><p><u>Active comparator study</u>&nbsp;&nbsp;</p><p>Resistance was studied by genotypic analysis of CMV in PMNL samples collected i) on Day 100 (end of study drug prophylaxis) and ii) in cases of suspected CMV disease up to 6 months after transplantation. From the 245 patients randomised to receive valganciclovir, 198 Day 100 samples were available for testing and no ganciclovir resistance mutations were observed. This compares with 2 ganciclovir resistance mutations detected in the 103 samples tested (1.9%) for patients in the oral ganciclovir comparator arm.&nbsp;</p><p>Of the 245 patients randomised to receive valganciclovir, samples from 50 patients with suspected CMV disease were tested and no resistance mutations were observed. Of the 127 patients randomised on the ganciclovir comparator arm, samples from 29 patients with suspected CMV disease were tested, from which two resistance mutations were observed, giving an incidence of resistance of 6.9%.&nbsp;</p><p><u>Extending prophylaxis study from 100 to 200 days post-transplant</u>&nbsp;&nbsp;</p><p>Genotypic analysis was performed on the UL54 and UL97 genes derived from virus extracted from 72 patients who met the resistance analysis criteria: patients who experienced a positive viral load (&gt;600 copies/ml) at the end of prophylaxis and/or patients who had confirmed CMV disease up to 12 months (52 weeks) post-transplant. Three patients in each treatment group had a known ganciclovir resistance mutation.&nbsp;</p><p><u>Paediatric population</u>&nbsp;&nbsp;</p><p><em>Treatment of CMV retinitis:</em>&nbsp;&nbsp;</p><p>The European Medicines Agency has waived the obligation to perform studies with Valgan oral Solution in all subsets of the paediatric population in the treatment of infection due to CMV in immuno-compromised patients (see section 4.2 for information on paediatric use).&nbsp;</p><p>Prevention of CMV disease in transplantation&nbsp; &nbsp;</p><p>A phase II pharmacokinetic and safety study in paediatric solid organ transplant recipients (aged 4 months to 16 years, n = 63) receiving valganciclovir once daily for up to 100 days according to the paediatric dosing algorithm (see section 4.2) produced exposures similar to that in adults (see section 5.2). Follow up after treatment was 12 weeks. CMV D/R serology status at baseline was D+/R- in 40%, D+/R+ in 38%, D-/R+ in 19% and D-/R- in 3% of the cases. Presence of CMV virus was reported in 7 patients. The observed adverse drug reactions were of similar nature as those in adults (see section 4.8).&nbsp;&nbsp;</p><p>A phase IV tolerability study in paediatric kidney transplant recipients (aged 1 to 16 years, n=57) receiving valganciclovir once daily for up to 200 days according to the dosing algorithm (see section 4.2) resulted in a low incidence of CMV. Follow up after treatment was 24 weeks. CMV D/R serology status at baseline was D+/R+ in 45%, D+/R- in 39%, D-/R+ in 7%, D-/R- in 7% and ND/R+ in 2% of the cases. CMV viremia was reported in 3 patients and a case of CMV syndrome was suspected in one patient but not confirmed by CMV PCR by the central laboratory. The observed adverse drug reactions were of similar nature to those in adults (see section 4.8).&nbsp;</p><p>These data support the extrapolation of efficacy data from adults to children and provide posology recommendations for paediatric patients.&nbsp;&nbsp;</p><p>A phase I pharmacokinetic and safety study in heart transplant patients (aged 3 weeks to 125 days, n=14) who received a single daily dose of valganciclovir according to the paediatric dosing algorithm (see section 4.2) on 2 consecutive days produced exposures similar to those in adults (see section 5.2). Follow up after treatment was 7 days. The safety profile was consistent with other paediatric and adult studies, although patient numbers and valganciclovir exposure were limited in this study.&nbsp;</p><p>Congenital CMV&nbsp; &nbsp;</p><p>The efficacy and safety of ganciclovir and/or valganciclovir was studied in neonates and infants with congenital symptomatic CMV infection in two studies.&nbsp;</p><p>In the first study, the pharmacokinetics and safety of a single dose of valganciclovir (dose range 14-16-20 mg/kg/dose) was studied in 24 neonates (aged 8 to34 days) with symptomatic congenital CMV disease (see section 5.2). The neonates received 6 weeks of antiviral treatment, whereas 19 of the 24 patients received up to 4 weeks of treatment with oral valganciclovir, in the remaining 2 weeks they received i.v. ganciclovir. The 5 remaining patients received i.v. ganciclovir for most of the study period. In the second study the efficacy and safety of six weeks versus six months of valganciclovir treatment was studied in 109 infants aged 2- to 30 days with symptomatic congenital CMV disease. All infants received oral valganciclovir at a dose of 16 mg/kg b.i.d. for 6 weeks. After 6 weeks of treatment the infants were randomized 1:1 to continue treatment with valganciclovir at the same dose or receive a matched placebo to complete 6 months of treatment.&nbsp;</p><p>This treatment indication is not currently recommended for valganciclovir. The design of the studies and results obtained are too limited to allow appropriate efficacy and safety conclusions on valganciclovir. &nbsp;</p><p><strong>&nbsp;</strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of valganciclovir have been evaluated in HIV- and</p><p>CMVseropositive patients, patients with AIDS and CMV retinitis and in solid organ transplant patients.&nbsp;</p><p>Dose proportionality with respect to ganciclovir AUC following administration of valganciclovir in the dose range 450 to 2625 mg was demonstrated only under fed conditions.&nbsp;</p><p><u>Absorption</u>&nbsp;&nbsp;</p><p>Valganciclovir is a prodrug of ganciclovir. It is well absorbed from the gastrointestinal tract and rapidly and extensively metabolised in the intestinal wall and liver to ganciclovir. Systemic exposure to valganciclovir is transient and low. The bioavailability of ganciclovir from oral dosing of valganciclovir is approximately 60% across all the patient populations studied and the resultant exposure to ganciclovir is similar to that after its intravenous administration (please see below).&nbsp;&nbsp;</p><p><em>Valganciclovir in HIV positive, CMV positive patients:</em>&nbsp;&nbsp;</p><p>Systemic exposure of HIV positive, CMV positive patients after twice daily administration of ganciclovir and valganciclovir for one week is:&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Parameter&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>Ganciclovir (5 mg/kg, IV) n</p><p>= 18&nbsp;</p></td><td colspan="2"><p>Valganciclovir (900 mg, p.o.) n</p><p>= 25&nbsp;</p></td></tr><tr><td><p>Ganciclovir&nbsp;</p></td><td><p>Valganciclovir&nbsp;</p></td></tr><tr><td><p>AUC(0 - 12 h) (&mu;g.h/ml) &nbsp;</p></td><td><p>28.6 &plusmn; 9.0&nbsp;</p></td><td><p>32.8 &plusmn; 10.1&nbsp;</p></td><td><p>0.37 &plusmn; 0.22&nbsp;</p></td></tr><tr><td><p>Cmax (&mu;g/ml) &nbsp;</p></td><td><p>10.4 &plusmn; 4.9&nbsp;</p></td><td><p>6.7 &plusmn; 2.1&nbsp;</p></td><td><p>0.18 &plusmn; 0.06&nbsp;</p></td></tr></tbody></table><p>The efficacy of ganciclovir in increasing the time-to-progression of CMV retinitis has been shown to correlate with systemic exposure (AUC).&nbsp;</p><p><em>Valganciclovir in solid organ transplant patients:</em>&nbsp;&nbsp;</p><p>Steady state systemic exposure of solid organ transplant patients to ganciclovir after daily oral administration of ganciclovir and valganciclovir is:&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Parameter&nbsp;</p></td><td rowspan="2"><p>Ganciclovir&nbsp;</p><p>(1000&nbsp; &nbsp;&nbsp;&nbsp; mg&nbsp;</p><p>times daily) n</p><p>= 82&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>three</p></td><td><p>&nbsp;Valganciclovir (900 mg, once daily)&nbsp; n = 161&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ganciclovir&nbsp;</p></td></tr><tr><td><p>AUC(0 - 24 h) (&mu;g.h/ml) &nbsp;</p></td><td><p>28.0 &plusmn; 10.9&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>46.3 &plusmn; 15.2&nbsp;</p></td></tr><tr><td><p>Cmax (&mu;g/ml) &nbsp;</p></td><td colspan="2"><p>1.4 &plusmn; 0.5&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td><td><p>5.3 &plusmn; 1.5&nbsp;</p></td></tr></tbody></table><p>The systemic exposure of ganciclovir to heart, kidney and liver transplant recipients was similar after oral administration of valganciclovir according to the renal function dosing algorithm.&nbsp;</p><p>Following the administration of valganciclovir as an oral solution, equivalent systemic ganciclovir exposures were obtained compared to the tablet formulation.&nbsp;</p><p><em>Food effect:</em>&nbsp;&nbsp;</p><p>When valganciclovir was given with food at the recommended dose of 900 mg, higher values were seen in both mean ganciclovir AUC (approximately 30%) and mean ganciclovir C<sub>max</sub> values (approximately 14%) than in the fasting state. Also, the inter-individual variation in exposure of ganciclovir decreases when taking Valgan oral Solution with food. Valgan oral Solution has only been administered with food in clinical studies. Therefore, it is recommended that Valgan oral Solution be administered with food (see section 4.2).&nbsp;</p><p><u>Distribution:</u>&nbsp;&nbsp;</p><p>Because of rapid conversion of valganciclovir to ganciclovir, protein binding of valganciclovir was not determined. The steady state volume of distribution (V<sub>d</sub>) of ganciclovir after intravenous administration was 0.680 &plusmn; 0.161 l/kg (n=114). For IV ganciclovir, the volume of distribution is correlated with body weight with values for the steady state volume of distribution ranging from 0.54-0.87 L/kg. Ganciclovir penetrates the cerebrospinal fluid. Binding to plasma proteins was 1%-2% over ganciclovir concentrations of 0.5 and 51 &micro;g/mL.&nbsp;</p><p><u>Biotransformation</u>&nbsp;&nbsp;</p><p>Valganciclovir is rapidly and extensively metabolised to ganciclovir; no other metabolites have been detected. Ganciclovir itself is not metabolised to a significant extent.&nbsp;</p><p><u>Elimination</u>&nbsp;&nbsp;</p><p>Following dosing with oral valganciclovir, the drug is rapidly hydrolysed to ganciclovir. Ganciclovir is eliminated from the systemic circulation by glomerular filtration and active tubular secretion. In patients with normal renal function greater than 90% of IV administered ganciclovir was recovered un-metabolized in the urine within 24 hours. In patients with normal renal function the post-peak plasma concentrations of ganciclovir after administration of valganciclovir decline with a half-life ranging from 0.4 h to 2.0 h.&nbsp;</p><p><u>Pharmacokinetics in special clinical situations</u>&nbsp;&nbsp;</p><p>Paediatric population&nbsp; &nbsp;</p><p>In a phase II pharmacokinetic and safety study in paediatric solid organ transplant recipients (aged</p><p>4 months to 16 years, n = 63) valganciclovir was given once daily for up to 100 days.</p><p>Pharmacokinetic parameters were similar across organ type and age range and comparable with adults. Population pharmacokinetic modeling suggested that bioavailability was approximately 60%. Clearance was positively influenced by both body surface area and renal function.&nbsp;&nbsp;</p><p>In a phase I pharmacokinetic and safety study in paediatric heart transplant recipients (aged 3 weeks to 125 days, n = 14), valganciclovir was given once daily for two study days. Population pharmacokinetics estimated that mean bioavailability was 64%.&nbsp;&nbsp;</p><p>A comparison of the results from these two studies and the pharmacokinetic results from the adult population shows that ranges of AUC <sub>0-24h </sub>were very similar across all age groups, including adults. Mean values for AUC<sub>0-24h </sub>and C<sub>max</sub> were also similar across the paediatric age groups &lt; 12 years old, although there was a trend of decreasing mean values for AUC<sub>0-24h </sub>and C<sub>max</sub> across the entire pediatric age range, which appeared to correlate with increasing age. This trend was more apparent for mean values of clearance and half-life (t<sub>1/2</sub>); however this is to be expected as clearance is influenced by changes in weight, height and renal function associated with patient growth, as indicated by population pharmacokinetic modelling.&nbsp;&nbsp;</p><p>The following table summarizes the model-estimated AUC<sub>0-24h </sub>ranges for ganciclovir from these two studies, as well as mean and standard deviation values for AUC<sub>0-24h,</sub> C<sub>max</sub>, CL and t &frac12; for the relevant paediatric age groups compared to adult data:&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td style="vertical-align:top"><p><strong>PK Parameter</strong>&nbsp;&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Adults*</strong>&nbsp;&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Paediatrics</strong>&nbsp;&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&ge; 18 years</strong></p><p><strong>(n=160)</strong>&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p><strong>&lt; 4 months </strong></p><p><strong>(n = 14)</strong>&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p><strong>4 months - &le; 2 years </strong>&nbsp;<strong>(n=17)</strong>&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;&gt; 2 - &lt; 12 years</strong>&nbsp; <strong>(n=21)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;&ge; 12 years &ndash; 16 </strong>&nbsp;<strong>years</strong>&nbsp; <strong>(n=25)</strong>&nbsp;&nbsp;</p></td></tr><tr><td><p><strong>AUC</strong><strong>0-24h </strong></p><p><strong>(&mu;g<sup>.</sup>h/ml)</strong>&nbsp;&nbsp;</p></td><td><p>46.3&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &plusmn;</p><p>15.2&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;68.1 &plusmn; 19.8&nbsp;</p></td><td style="vertical-align:top"><p>64.3 &plusmn; 29.2&nbsp;</p></td><td style="vertical-align:top"><p>59.2 &plusmn; 15.1&nbsp;</p></td><td style="vertical-align:top"><p>50.3 &plusmn; 15.0&nbsp;</p></td></tr><tr><td><p><strong>Range of AUC<sub>0-</sub></strong></p><p><strong>24h</strong>&nbsp;&nbsp;</p></td><td><p>15.4&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ndash;</p><p>116.1&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;34 - 124&nbsp;</p></td><td style="vertical-align:top"><p>34 - 152&nbsp;</p></td><td style="vertical-align:top"><p>36 - 108&nbsp;</p></td><td style="vertical-align:top"><p>22 - 93&nbsp;</p></td></tr><tr><td><p><strong>C</strong><strong>max (&mu;g/ml)</strong>&nbsp;&nbsp;</p></td><td><p>5.3 &plusmn; 1.5&nbsp;</p></td><td><p>10.5 &plusmn; 3.36&nbsp;</p></td><td><p>10.3 &plusmn; 3.3&nbsp;</p></td><td><p>9.4 &plusmn; 2.7&nbsp;</p></td><td><p>8.0 &plusmn; 2.4&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Clearance (l/h)</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;12.7 &plusmn; 4.5&nbsp;</p></td><td><p>1.25&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &plusmn;</p><p>0.473&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;2.5 &plusmn; 2.4&nbsp;</p></td><td style="vertical-align:top"><p>4.5 &plusmn; 2.9&nbsp;</p></td><td style="vertical-align:top"><p>6.4 &plusmn; 2.9&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>t<sub>1/2</sub> (h)</strong>&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>6.5 &plusmn; 1.4&nbsp;</p></td><td><p>1.97&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &plusmn;</p><p>0.185&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;3.1 &plusmn;1.4&nbsp;</p></td><td style="vertical-align:top"><p>4.1 &plusmn; 1.3&nbsp;</p></td><td style="vertical-align:top"><p>5.5 &plusmn; 1.1&nbsp;</p></td></tr></tbody></table><p>* Extracted from study report PV 16000&nbsp;</p><p>The once daily dose of Valgan oral Solution in both of the studies described above was based on body surface area (BSA) and creatinine clearance (CrCl) derived from a modified Schwartz formula, and was calculated using the dosing algorithm presented in section 4.2.&nbsp;</p><p>Ganciclovir pharmacokinetics following valganciclovir administration were also evaluated in two studies in neonates and infants with symptomatic congenital CMV disease. In the first study 24 neonates aged 8 to 34 days received 6 mg/kg intravenous ganciclovir twice daily. Patients were then treated with oral valganciclovir, where the dose of valganciclovir powder for oral solution ranged from 14 mg/kg to 20 mg/kg twice daily; total treatment duration was 6 weeks. A dose of 16 mg/kg twice daily of valganciclovir powder for oral solution provided comparable ganciclovir exposure as 6 mg/kg intravenous ganciclovir twice daily in neonates, and also achieved ganciclovir exposure similar to the effective adult 5 mg/kg intravenous dose.&nbsp;&nbsp;</p><p>In the second study, 109 neonates aged 2 to 30 days received 16 mg/kg valganciclovir powder for oral solution twice daily for 6 weeks and subsequently 96 out of 109 enrolled patients were randomized to continue receiving valganciclovir or placebo for 6 months. However, the mean AUC<sub>0-12h</sub> was lower compared to the mean AUC<sub>0-12h</sub> values from the first study. The following table shows the mean values of AUC, C<sub>max</sub>, and t<sub>&frac12; </sub>including standard deviations compared with adult data:&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td style="vertical-align:top"><p><strong>PK Parameter</strong>&nbsp;&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Adults&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Paediatrics (neonates and infants)&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>5 mg/kg GAN</strong>&nbsp;&nbsp;</p><p><strong>Single dose</strong>&nbsp;&nbsp;</p><p><strong>(n=8)</strong>&nbsp;&nbsp;</p></td><td><p><strong>6 mg/kg GAN</strong>&nbsp;&nbsp;</p><p><strong>Twice daily</strong>&nbsp;</p><p><strong>(n=19)</strong>&nbsp;</p></td><td><p><strong>16 mg/kg VAL</strong>&nbsp;&nbsp;</p><p><strong>Twice daily</strong>&nbsp;&nbsp;</p><p><strong>(n=19)</strong>&nbsp;&nbsp;</p></td><td><p><strong>16 mg/kg VAL</strong>&nbsp;&nbsp;</p><p><strong>Twice daily</strong>&nbsp;&nbsp;</p><p><strong>(n = 100)</strong>&nbsp;&nbsp;</p></td></tr><tr><td><p><strong>AUC<sub>0-&infin;</sub> (&mu;g<sup>.</sup>h/mL)</strong>&nbsp;&nbsp;</p></td><td><p>25.4 &plusmn; 4.32&nbsp;</p></td><td><p><strong>-</strong>&nbsp;&nbsp;</p></td><td><p>-&nbsp;</p></td><td><p>-&nbsp;</p></td></tr><tr><td><p><strong>AUC</strong><strong>0-12h (&mu;g<sup>.</sup>h/mL)</strong>&nbsp;&nbsp;</p></td><td><p>-&nbsp;</p></td><td><p>38.2 &plusmn; 42.7&nbsp;</p></td><td><p>30.1 &plusmn; 15.1&nbsp;</p></td><td><p>20.85 &plusmn; 5.40&nbsp;</p></td></tr><tr><td><p><strong>C</strong><strong>max (&mu;g/ml)</strong>&nbsp;&nbsp;</p></td><td><p>9.03 &plusmn; 1.26&nbsp;</p></td><td><p>12.9 &plusmn; 21.5&nbsp;</p></td><td><p>5.44 &plusmn; 4. 04&nbsp;</p></td><td><p>-&nbsp;</p></td></tr><tr><td><p><strong>t<sub>1/2</sub> (h)</strong>&nbsp;&nbsp;</p></td><td><p>3.32 &plusmn; 0.47&nbsp;</p></td><td><p>2.52 &plusmn; 0. 55&nbsp;</p></td><td><p>2.98 &plusmn; 1. 26&nbsp;</p></td><td><p>2.98 &plusmn; 1.12&nbsp;</p></td></tr></tbody></table><p>GAN = Ganciclovir, i.v. VAL = Valganciclovir, oral&nbsp;</p><p>These data are too limited to allow conclusions regarding efficacy or posology recommendations for paediatric patients with congenital CMV infection.&nbsp;</p><p>Elderly&nbsp; &nbsp;</p><p>No investigations on valganciclovir or ganciclovir pharmacokinetics in adults older than 65 years of age have been undertaken (see section 4.2).&nbsp;</p><p>Patients with renal impairment&nbsp; &nbsp;</p><p>The pharmacokinetics of ganciclovir from a single oral dose of 900 mg valganciclovir was evaluated in 24 otherwise healthy individuals with renal impairment.&nbsp;</p><p>Pharmacokinetic parameters of ganciclovir from a single oral dose of 900 mg Valgan oral Solution tablets in patients with various degrees of renal impairment:&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td><p><strong>Estimated </strong>&nbsp;</p><p><strong>Creatinine </strong>&nbsp;</p><p><strong>Clearance </strong>&nbsp;</p><p><strong>(mL/min)</strong>&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p><strong>N</strong>&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p><strong>Apparent &nbsp;&nbsp;&nbsp;&nbsp; Clearance</strong></p><p><strong>(mL/min) Mean </strong>&plusmn; <strong>SD </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>AUClast (&mu;g∙h/mL)</strong><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span> SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_44204"
   o:spid="_x0000_s1026" style='width:3pt;height:10.7pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="38100,136178" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:rect id="Rectangle_x0020_44186" o:spid="_x0000_s1027" style='position:absolute;
    width:50673;height:181116;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
       margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
       line-height:107%'><b style='mso-bidi-font-weight:normal'><span
       style='mso-spacerun:yes'> </span></b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><w:wrap type="none" anchorx="page"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="9" height="23" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1026" type="#_x0000_t75" style='width:3pt;height:10.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;<strong>Mean </strong>&plusmn; <strong>SD</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Half-life (hours) Mean </strong>&plusmn;</p><p><strong>SD</strong>&nbsp;</p></td></tr><tr><td><p>51-70&nbsp;&nbsp;</p></td><td><p>6&nbsp;&nbsp;</p></td><td><p>249 &plusmn; 99&nbsp;&nbsp;</p></td><td><p>49.5 &plusmn; 22.4&nbsp;&nbsp;</p></td><td><p>4.85 &plusmn; 1.4&nbsp;&nbsp;</p></td></tr><tr><td><p>21-50&nbsp;&nbsp;</p></td><td><p>6&nbsp;&nbsp;</p></td><td><p>136 &plusmn; 64&nbsp;&nbsp;</p></td><td><p>91.9 &plusmn; 43.9&nbsp;&nbsp;</p></td><td><p>10.2 &plusmn; 4.4&nbsp;&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>11-20&nbsp;&nbsp;</p><p>&le; 10</p></td><td><p>6&nbsp;&nbsp;</p></td><td><p>45 &plusmn; 11&nbsp;&nbsp;</p></td><td><p>223 &plusmn; 46&nbsp;&nbsp;</p></td><td><p>21.8 &plusmn; 5.2&nbsp;&nbsp;</p></td></tr><tr><td><p>6&nbsp;&nbsp;</p></td><td><p>12.8 &plusmn; 8&nbsp;&nbsp;</p></td><td><p>366 &plusmn; 66&nbsp;&nbsp;</p></td><td><p>67.5 &plusmn; 34&nbsp;&nbsp;</p></td></tr></tbody></table><p>Decreasing renal function resulted in decreased clearance of ganciclovir from valganciclovir with a corresponding increase in terminal half-life. Therefore, dosage adjustment is required for renally impaired patients (see sections 4.2 and 4.4).&nbsp;&nbsp;</p><p>Patients undergoing haemodialysis&nbsp; &nbsp;</p><p>For patients receiving haemodialysis Valgan oral Solution powder for oral solution is recommended to provide an individualised dose (see sections 4.2 and 4.4).&nbsp;</p><p>Stable liver transplant patients&nbsp; &nbsp;</p><p>The pharmacokinetics of ganciclovir from valganciclovir in stable liver transplant patients were investigated in one open label 4-part crossover study (N=28). The bioavailability of ganciclovir from valganciclovir, following a single dose of 900 mg valganciclovir under fed conditions, was approximately 60%. Ganciclovir AUC<sub>0-24h </sub>was comparable to that achieved by 5 mg/kg intravenous ganciclovir in liver transplant patients.&nbsp;</p><p>Patients with hepatic impairment&nbsp; &nbsp;</p><p>The safety and efficacy of Valgan oral Solution have not been studied in patients with hepatic impairment. Hepatic impairment should not significantly affect the pharmacokinetics of ganciclovir since it is excreted renally and, therefore, no specific dose recommendation is made.&nbsp;</p><p>Patients with cystic fibrosis&nbsp; &nbsp;</p><p>In a phase I pharmacokinetic study in lung transplant recipients with or without cystic fibrosis (CF), 31 patients (16 CF/15 non-CF) received post-transplant prophylaxis with 900 mg/day Valgan oral Solution. The study indicated that cystic fibrosis had no statistically significant influence on the overall average systemic exposure to ganciclovir in lung transplant recipients. Ganciclovir exposure in lung transplant recipients was comparable to that shown to be efficacious in the prevention of CMV disease in other solid organ transplant recipients.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valganciclovir is a pro-drug of ganciclovir and therefore effects observed with ganciclovir apply equally to valganciclovir. Toxicity of valganciclovir in pre-clinical safety studies was the same as that seen with ganciclovir and was induced at ganciclovir exposure levels comparable to, or lower than, those in humans given the induction dose.&nbsp;&nbsp;</p><p>These findings were gonadotoxicity (testicular cell loss) and nephrotoxicity (uraemia, cell degeneration), which were irreversible; myelotoxicity (anaemia, neutropenia, lymphocytopenia) and gastrointestinal toxicity (mucosal cell necrosis), which were reversible.&nbsp;</p><p>Ganciclovir was mutagenic in mouse lymphoma cells and clastogenic in mammalian cells. Such results are consistent with the positive mouse carcinogenicity study with ganciclovir. Ganciclovir is a potential carcinogen.&nbsp;</p><p>Further studies have shown ganciclovir to be teratogenic, embryotoxic, to inhibit spermatogenesis (i.e. impair male fertility) and to suppress female fertility.&nbsp;</p><p>Animal data indicate that ganciclovir is excreted in the milk of lactating rats.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valganciclovir for oral solution 50 mg/1mL&nbsp;</p><p>The other ingredients are: Mannitol, USP (Pearlitol SD200), Povidone, USP (Kollidon 30), Sodium benzoate,&nbsp; USP-NF, Saccharin Sodium, USP, Anhydrous Citric acid, USP, Tutti-Frutti flavour</p><p>051880 AP0551, HIS and&nbsp; Purified Water IHS/USP/Ph.Eur&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>storage </strong>&nbsp;Powder<strong>: </strong>Store below 25&ordm;C.&nbsp;</p><p>Reconstituted solution: Store in a refrigerator (2&deg;C - 8&deg;C). &ldquo; Do not freeze&rdquo;.</p><p>The shelf-life of the oral solution is 49 days. Do not use the solution 49 days after preparation or after the expiry date which will be written on the bottle by the pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>Bottle pack&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Hetero Co.  
Aljameah Street, Malaz quarter,  
Riyadh 11441, Saudi Arabia  
Tel: 	+966 11 4772215     
Manufacture:  
Hetero Lab Limited Unit V, Hyderabad, India.  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2022  
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>